BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37342057)

  • 1. Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis.
    Morot J; Del Duca E; Chastagner M; Fernandes M; Estrada Y; Lefevre MA; Kanitakis J; Harou O; Jullien D; Nicolas JF; Krueger JG; Vocanson M; Guttman-Yassky E; Villani AP
    JAMA Dermatol; 2023 Aug; 159(8):820-829. PubMed ID: 37342057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
    Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
    Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling.
    Rochman Y; Kashyap M; Robinson GW; Sakamoto K; Gomez-Rodriguez J; Wagner KU; Leonard WJ
    Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19455-60. PubMed ID: 20974963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
    Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
    Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
    Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
    Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression patterns of three JAK-STAT pathway genes in feather follicle development during chicken embryogenesis.
    Tao Y; Zhou X; Liu Z; Zhang X; Nie Y; Zheng X; Li S; Hu X; Yang G; Zhao Q; Mou C
    Gene Expr Patterns; 2020 Jan; 35():119078. PubMed ID: 31759166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of Yisui Jiedu Recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia].
    Tian SL; Zhou YM; Huang T; Xue ZZ; He W
    Zhong Xi Yi Jie He Xue Bao; 2008 Feb; 6(2):185-9. PubMed ID: 18241656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
    Quintás-Cardama A; Verstovsek S
    Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LPS-induced SOCS3 antagonizes the JAK2-STAT5 pathway and inhibits β-casein synthesis in bovine mammary epithelial cells.
    Geng Z; Shan X; Lian S; Wang J; Wu R
    Life Sci; 2021 Aug; 278():119547. PubMed ID: 33930363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CUZD1 is a critical mediator of the JAK/STAT5 signaling pathway that controls mammary gland development during pregnancy.
    Mapes J; Li Q; Kannan A; Anandan L; Laws M; Lydon JP; Bagchi IC; Bagchi MK
    PLoS Genet; 2017 Mar; 13(3):e1006654. PubMed ID: 28278176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
    Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
    Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desensitization of the growth hormone-induced Janus kinase 2 (Jak 2)/signal transducer and activator of transcription 5 (Stat5)-signaling pathway requires protein synthesis and phospholipase C.
    Fernández L; Flores-Morales A; Lahuna O; Sliva D; Norstedt G; Haldosén LA; Mode A; Gustafsson JA
    Endocrinology; 1998 Apr; 139(4):1815-24. PubMed ID: 9528967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK kinases overexpression promotes in vitro cell transformation.
    Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
    Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6.
    Jiang L; Zhao XH; Mao YL; Wang JF; Zheng HJ; You QS
    J Exp Clin Cancer Res; 2019 Nov; 38(1):465. PubMed ID: 31718693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
    Collotta D; Hull W; Mastrocola R; Chiazza F; Cento AS; Murphy C; Verta R; Alves GF; Gaudioso G; Fava F; Yaqoob M; Aragno M; Tuohy K; Thiemermann C; Collino M
    Mol Metab; 2020 Sep; 39():101009. PubMed ID: 32413585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy.
    Tao J; Mariani L; Eddy S; Maecker H; Kambham N; Mehta K; Hartman J; Wang W; Kretzler M; Lafayette RA
    Clin J Am Soc Nephrol; 2020 Jul; 15(7):973-982. PubMed ID: 32354727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
    Aota K; Yamanoi T; Kani K; Ono S; Momota Y; Azuma M
    Inflammation; 2021 Feb; 44(1):206-216. PubMed ID: 32772240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of JAK1 Drives Innate Immune Deficiency.
    Witalisz-Siepracka A; Klein K; Prinz D; Leidenfrost N; Schabbauer G; Dohnal A; Sexl V
    Front Immunol; 2018; 9():3108. PubMed ID: 30671064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation.
    Hintzen C; Evers C; Lippok BE; Volkmer R; Heinrich PC; Radtke S; Hermanns HM
    J Biol Chem; 2008 Jul; 283(28):19465-77. PubMed ID: 18430728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.